drugset / Trial / NCT06944145
New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia
Phase 2
Recruiting
242 enrolled
Beth Israel Deaconess Medical Center
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
SRD5A2 is a critical enzyme for prostatic development and growth, and the SRD5A2 inhibitor, finasteride, is used to treat benign prostatic hyperplasia (BPH). SRD5A2 is absent in 30% of normal adult men, which explains the resistance of a subset of patients to this commonly prescribed drug. This project proposes new combination therapies (5-ARI+raloxifene) and evaluates novel non-invasive biomarkers, based on alternative pathways that lead to prostatic enlargement.
Timeline
- Start
- 2025-12-03
- Primary completion
- 2029-06-01
- Completion
- 2030-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Finasteride | Small molecule | 5 mg | Oral |
| Subject | Raloxifene | Other / unclassified | 60 mg | Oral |